-+ 0.00%
-+ 0.00%
-+ 0.00%

Kalaris Therapeutics Q4 EPS $(0.44) Beats $(0.56) Estimate

Benzinga·03/17/2026 12:13:52
Listen to the news
Kalaris Therapeutics (NASDAQ:KLRS) reported quarterly losses of $(0.44) per share which beat the analyst consensus estimate of $(0.56) by 21.01 percent.